Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Partners with Stratec to Develop Automated Array Analysis System

Premium

By Justin Petrone

Quanterix has partnered with Stratec Biomedical to develop an automated analysis system for processing its single molecule arrays. Cambridge, Mass.-based Quanterix expects to launch a research use instrument in 2013, followed by the commercialization of an in vitro diagnostics platform a year later.

Under the terms of the agreement, Quanterix will receive access to Brinkfeld, Germany-based Stratec's technology, which will be customized to optimize and automate the advanced applications of Quanterix's platform. As part of the deal, Stratec will receive payments, as well as a minority stake of approximately 7 percent in the share capital of Quanterix, upon the achievement of technological milestones.

After completion of the development phase, Stratec will manufacture and supply the system and Quanterix has committed to order an agreed minimum volume of systems.

Martin Madaus, Quanterix's executive chairman, said in a statement that the deal will enable Quanterix to "bring our single molecule detection technology to the market in a format that will address the needs of both clinical labs, as well as individual research scientists."

Further details of the deal were not disclosed.

Quanterix announced a similar agreement last month with Sony DADC. Under the terms of that deal, Quanterix's single-molecule arrays will be manufactured on optical discs by Sony DADC. The Salzburg, Austria-based firm also manufactures CDs, DVDs, and Blu-ray Discs (BAN 7/26/2011).

A company spokesperson confirmed with BioArray News this week that the Sony-manufactured consumables will run on the Stratec-manufactured system.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.